Lupus Nephritis Global Market Report 2025

Description

Lupus nephritis is a severe kidney condition caused by systemic lupus erythematosus (SLE), an autoimmune disease in which the immune system erroneously attacks healthy tissues, including the kidneys. This inflammation can result in kidney damage, reduced function, and, if left untreated, potentially lead to kidney failure. Early diagnosis and treatment are essential for managing the disease effectively.

Lupus nephritis progresses through different stages, including class 1, class 2, class 3, and others. Class 1 represents a stage with minimal kidney damage, where kidney function remains stable, and symptoms are generally not apparent. Treatment at this stage focuses on preventing further progression of the disease. Common drug classes used in treatment include immunosuppressive drugs, corticosteroids, biological agents, and antimalarial drugs, which can be administered orally, parenterally, and through other routes. These treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, with end users such as hospitals, specialty clinics, and others.

The lupus nephritis market research report is one of a series of new reports from The Business Research Company that provides lupus nephritis market statistics, including lupus nephritis industry global market size, regional shares, competitors with a lupus nephritis market share, detailed lupus nephritis market segments, market trends and opportunities, and any further data you may need to thrive in the lupus nephritis industry. This lupus nephritis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The lupus nephritis market size has grown strongly in recent years. It will grow from $1.94 billion in 2024 to $2.09 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth during the historic period can be attributed to factors such as increased research investments in lupus nephritis, a rising incidence of autoimmune diseases, higher healthcare spending, the growing adoption of biologics, and the increasing popularity of telemedicine.

The lupus nephritis market size is expected to see strong growth in the next few years. It will grow to $2.80 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth during the forecast period can be attributed to factors such as the rising awareness among physicians, greater adoption of biologic therapies, an increasing number of specialty clinics, a growing emphasis on renal transplantation, and improved access to nephrology services. Key trends in the forecast period include advancements in biologic therapies, personalized medicine approaches, the discovery of novel diagnostic biomarkers, an expansion of clinical trials, and progress in stem cell therapy.

The increasing prevalence of genetic predisposition is expected to drive the growth of the lupus nephritis market in the future. Genetic predisposition refers to inherited genetic traits that make an individual more likely to develop certain diseases or conditions. Factors such as inheritance, environmental influences, and gene mutations contribute to the rising prevalence of genetic predisposition. This predisposition plays a key role in the development of lupus nephritis, highlighting the influence of inherited genetic factors in autoimmune diseases, particularly those affecting kidney function. For example, in October 2024, the Cystic Fibrosis Trust reported that the UK CF Registry recorded 11,148 patients in 2022, which increased to 11,318 in 2024, reflecting a 1.52% rise in cystic fibrosis (CF) patients. Therefore, the growing prevalence of genetic predisposition is contributing to the growth of the lupus nephritis market.

Companies in the lupus nephritis market are focusing on developing advanced second-generation calcineurin inhibitors to improve treatment outcomes and long-term kidney function for patients. These inhibitors are used in lupus nephritis to reduce inflammation and prevent kidney damage by modulating immune responses. For example, in September 2024, Aurinia Pharmaceuticals Inc. received approval from the Japanese Ministry of Health, Labour, and Welfare for LUPKYNIS (voclosporin) as a treatment for lupus nephritis. This approval allows voclosporin to be used in combination with mycophenolate mofetil (MMF), based on the positive results from the AURORA Clinical Program, which demonstrated the drug's safety and efficacy. This approval marks a significant step forward in expanding treatment options for lupus nephritis patients in Japan, improving both disease management and outcomes.

In March 2024, Lupus Therapeutics, an affiliate clinical research partner of the Lupus Research Alliance, partnered with Artiva Biotherapeutics Inc. to support a clinical trial for lupus nephritis. This collaboration aims to conduct a Phase 1 trial to evaluate Artiva's AlloNK therapy with anti-CD20 antibodies for patients with active lupus nephritis. The trial will assess the safety and effectiveness of this potential treatment for this severe kidney complication. Artiva Biotherapeutics is a biotechnology company based in the US that develops treatments for lupus nephritis.

Major players in the lupus nephritis market are F. Hoffmann-La Roche Ltd., Bristol Myers Squibb, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Genentech, Astrazeneca PLC, Biocon Biologics, Hanmi Pharmaceutical Co. Ltd., Sana Biotechnology Inc., RemeGen Co. Ltd., Aurinia Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., Equillium Inc., Anthera Pharmaceuticals Inc., Atara Biotherapeutics Inc., Artiva Biotherapeutics, Caribou Biosciences, Nkarta Inc., Adicet Bio Inc., Lupus Research Alliance, Kyverna Therapeutics Inc., Kezar Life Sciences, and Bionxt Solutions.

Asia-Pacific was the largest region in the lupus nephritis market in 2024. The regions covered in lupus nephritis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the lupus nephritis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The lupus nephritis market consists of revenues earned by entities by providing services such as dialysis services, diagnostic testing, renal care services, and home healthcare services. The market value includes the value of related goods sold by the service provider or included within the service offering. The lupus nephritis market also consists of sales of medical devices, diagnostic products, and renal replacement products. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Lupus Nephritis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on lupus nephritis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for lupus nephritis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The lupus nephritis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Stage: Class 1; Class 2; Class 3; Other Stages
2) By Drug Class: Immunosuppressive Drugs; Corticosteroids; Biological Agents; Antimalarial Drugs
3) Route Of Administration: Oral; Parenteral; Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
5) By End-User: Hospitals; Specialty Clinics; Other End-Users
Subsegments:
1) By Class 1: Asymptomatic Cases; Mild Proteinuria; Incidental Diagnosis.
2) By Class 2: Mild Hematuria; Low-Grade Proteinuria; Minimal Immune Complex Deposition.
3) By Class 3: Active Lesions; Chronic Sclerotic Lesions; Crescent Formation.
4) By Other Stages: Class 4 (Diffuse Lupus Nephritis); Class 5 (Membranous Lupus Nephritis); Class 6 (Advanced Sclerotic Lupus Nephritis)
Companies Mentioned: F. Hoffmann-La Roche Ltd.; Bristol Myers Squibb; Novartis AG; GlaxoSmithKline plc; Eli Lilly and Company
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r34608

1. Executive Summary

2. Lupus Nephritis Market Characteristics

3. Lupus Nephritis Market Trends And Strategies

4. Lupus Nephritis Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Lupus Nephritis Growth Analysis And Strategic Analysis Framework

5.1. Global Lupus Nephritis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Lupus Nephritis Market Growth Rate Analysis
5.4. Global Lupus Nephritis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Lupus Nephritis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Lupus Nephritis Total Addressable Market (TAM)

6. Lupus Nephritis Market Segmentation

6.1. Global Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Class 1
Class 2
Class 3
Other Stages
6.2. Global Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immunosuppressive Drugs
Corticosteroids
Biological Agents
Antimalarial Drugs
6.3. Global Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Parenteral
Other Routes Of Administration
6.4. Global Lupus Nephritis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
6.5. Global Lupus Nephritis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Speciality Clinics
Other End-Users
6.6. Global Lupus Nephritis Market, Sub-Segmentation Of Class 1, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Asymptomatic Cases
Mild Proteinuria
Incidental Diagnosis
6.7. Global Lupus Nephritis Market, Sub-Segmentation Of Class 2, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Mild Hematuria
Low-Grade Proteinuria
Minimal Immune Complex Deposition
6.8. Global Lupus Nephritis Market, Sub-Segmentation Of Class 3, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Active Lesions
Chronic Sclerotic Lesions
Crescent Formation
6.9. Global Lupus Nephritis Market, Sub-Segmentation Of Other Stages, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Class 4 (Diffuse Lupus Nephritis)
Class 5 (Membranous Lupus Nephritis)
Class 6 (Advanced Sclerotic Lupus Nephritis)

7. Lupus Nephritis Market Regional And Country Analysis

7.1. Global Lupus Nephritis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Lupus Nephritis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Lupus Nephritis Market

8.1. Asia-Pacific Lupus Nephritis Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Lupus Nephritis Market

9.1. China Lupus Nephritis Market Overview
9.2. China Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Lupus Nephritis Market

10.1. India Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Lupus Nephritis Market

11.1. Japan Lupus Nephritis Market Overview
11.2. Japan Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Lupus Nephritis Market

12.1. Australia Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Lupus Nephritis Market

13.1. Indonesia Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Lupus Nephritis Market

14.1. South Korea Lupus Nephritis Market Overview
14.2. South Korea Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Lupus Nephritis Market

15.1. Western Europe Lupus Nephritis Market Overview
15.2. Western Europe Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Lupus Nephritis Market

16.1. UK Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Lupus Nephritis Market

17.1. Germany Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Lupus Nephritis Market

18.1. France Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Lupus Nephritis Market

19.1. Italy Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Lupus Nephritis Market

20.1. Spain Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Lupus Nephritis Market

21.1. Eastern Europe Lupus Nephritis Market Overview
21.2. Eastern Europe Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Lupus Nephritis Market

22.1. Russia Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Lupus Nephritis Market

23.1. North America Lupus Nephritis Market Overview
23.2. North America Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Lupus Nephritis Market

24.1. USA Lupus Nephritis Market Overview
24.2. USA Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Lupus Nephritis Market

25.1. Canada Lupus Nephritis Market Overview
25.2. Canada Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Lupus Nephritis Market

26.1. South America Lupus Nephritis Market Overview
26.2. South America Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Lupus Nephritis Market

27.1. Brazil Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Lupus Nephritis Market

28.1. Middle East Lupus Nephritis Market Overview
28.2. Middle East Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Lupus Nephritis Market

29.1. Africa Lupus Nephritis Market Overview
29.2. Africa Lupus Nephritis Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Lupus Nephritis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Lupus Nephritis Market, Segmentation Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Lupus Nephritis Market Competitive Landscape And Company Profiles

30.1. Lupus Nephritis Market Competitive Landscape
30.2. Lupus Nephritis Market Company Profiles
- 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Bristol Myers Squibb Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

31. Lupus Nephritis Market Other Major And Innovative Companies

31.1. Genentech
31.2. Astrazeneca PLC
31.3. Biocon Biologics
31.4. Hanmi Pharmaceutical Co. Ltd.
31.5. Sana Biotechnology Inc.
31.6. RemeGen Co. Ltd.
31.7. Aurinia Pharmaceuticals Inc.
31.8. Otsuka Pharmaceutical Co. Ltd.
31.9. Equillium Inc.
31.10. Anthera Pharmaceuticals Inc.
31.11. Atara Biotherapeutics Inc.
31.12. Artiva Biotherapeutics
31.13. Caribou Biosciences
31.14. Nkarta Inc.
31.15. Adicet Bio Inc.

32. Global Lupus Nephritis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Lupus Nephritis Market

34. Recent Developments In The Lupus Nephritis Market

35. Lupus Nephritis Market High Potential Countries, Segments and Strategies

35.1 Lupus Nephritis Market In 2029 - Countries Offering Most New Opportunities
35.2 Lupus Nephritis Market In 2029 - Segments Offering Most New Opportunities
35.3 Lupus Nephritis Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer